UK markets closed

LeMaitre Vascular, Inc. (LMAT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
64.19-0.04 (-0.06%)
As of 02:54PM EDT. Market open.

LeMaitre Vascular, Inc.

63 Second Avenue
Burlington, MA 01803
United States
781 221 2266
https://www.lemaitre.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full-time employees614

Key executives

NameTitlePayExercisedYear born
Mr. George W. LeMaitreChairman & CEO1.12M1.31M1965
Mr. David B. RobertsPresident & Director634.85k1.24M1964
Mr. Joseph P. Pellegrino Jr.CFO, Secretary & Director566.19kN/A1965
Mr. Trent G. KamkeSenior Vice President of Operations445.38k80.43k1971
Dr. George D. LeMaitreFounder and Chairman of Scientific Advisory Board118.48kN/A1934
Mr. David C. HissongVP & General CounselN/AN/A1970
Ms. Kimberly L. CieslakVice President of MarketingN/AN/A1973
Mr. Daniel J. MumfordSenior Director of Human ResourcesN/AN/A1982
Mr. Maik D. HelmersSenior Vice President of Sales – Central EuropeN/AN/A1974
Mr. Ryan H. ConnellySenior Vice President of Advanced Manufacturing EngineeringN/AN/A1977
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Corporate governance

LeMaitre Vascular, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.